Myristoyl lysophosphatidylcholine is a biomarker and potential therapeutic target for community-acquired pneumonia
There is no gold standard for evaluating the severity of community-acquired pneumonia (CAP), and it is still based on a score. This study aimed to use the metabolomics method to find promised biomarkers in assessing disease severity and potential therapeutic targets for CAP. The result found that th...
Main Authors: | Wengang Nan, Fen Xiong, Hong Zheng, Chen Li, Cong Lou, Xiong Lei, Huizhen Wu, Hongchang Gao, Yuping Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-12-01
|
Series: | Redox Biology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2213231722003287 |
Similar Items
-
Inflammasome Sensor NLRP1 Confers Acquired Drug Resistance to Temozolomide in Human Melanoma
by: Zili Zhai, et al.
Published: (2020-09-01) -
Lysophosphatidylcholine acyltransferase level predicts the severity and prognosis of patients with community-acquired pneumonia: a prospective multicenter study
by: Li Chen, et al.
Published: (2024-01-01) -
Predictive Value of Lysophosphatidylcholine for Determining the Disease Severity and Prognosis of Elderly Patients with Community-Acquired Pneumonia
by: Gu M, et al.
Published: (2024-03-01) -
Community-acquired pneumonia /
by: Suttorp, N. (Norbert), 1953-, et al.
Published: (2007) -
Hospital Acquired Pneumonia
by: Halis AKALIN, et al.
Published: (1999-12-01)